Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Puma Biotechnology, Inc. (PBYI)
USD8.36
+0.08 (+0.91%)
US NASDAQ Healthcare Biotechnology
Address
10880 Wilshire Boulevard 90024
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Alan H. Auerbach
Website
pumabiotechnology.com
IPO
2012-04-24
CIK 1401667 ISIN US74587V1070
Description
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.36
+0.08 (+0.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
285.5K
Beta
1.19
Float Shares
39.07M
Free Float %
76.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.84% | -5.85% | -9.00% | +4.12% | +41.88% | +18.99% | +132.89% | +151.06% | -27.16% | -68.34% | -49.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
8.36
DCF (Unlevered)
17.31
+107.2%
DCF (Levered)
17.55
+110.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.70
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-0.9% Q1'26: -2.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1.6% Q1'26: -223.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.0% Q1'26: +34.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+18.6% ★ Q1'26: -8.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+60.1% ★ Q1'26: -35.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.2% ★ Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.54× ★ Q1'26: -3.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
27.70M
est: 26.91M (+2.9%)
|
251.00M
est: 234.90M (+6.9%)
|
272.26M
est: 269.67M (+1.0%)
|
225.11M
est: 225.38M (-0.1%)
|
253.16M
est: 245.09M (+3.3%)
|
228.03M
est: 219.41M (+3.9%)
|
235.64M
est: 219.14M (+7.5%)
|
230.47M
est: 223.89M (+2.9%)
|
228.37M
est: 221.50M (+3.1%)
|
222.00M
222.00M – 222.00M
+0.2% YoY
|
219.00M
219.00M – 219.00M
-1.4% YoY
|
216.00M
215.00M – 217.00M
-1.4% YoY
|
213.00M
213.00M – 213.00M
-1.4% YoY
|
210.00M
210.00M – 210.00M
-1.4% YoY
|
| EBITDA |
-288.42M
est: 1.77M (-16,385.1%)
|
-95.21M
est: -108.71M (+12.4%)
|
-52.45M
est: -60.43M (+13.2%)
|
-35.71M
est: -18.21M (-96.0%)
|
-4.69M
est: 16.13M (-129.1%)
|
21.89M
est: -108.86M (+120.1%)
|
47.52M
est: 100.89M (-52.9%)
|
48.08M
est: 103.08M (-53.4%)
|
53.34M
est: 101.98M (-47.7%)
|
102.21M
102.21M – 102.21M
+0.2% YoY
|
100.83M
100.83M – 100.83M
-1.4% YoY
|
99.44M
98.98M – 99.91M
-1.4% YoY
|
98.06M
98.06M – 98.06M
-1.4% YoY
|
96.68M
96.68M – 96.68M
-1.4% YoY
|
| EBIT |
-291.24M
est: 526.6K (-55,407.7%)
|
-102.59M
est: -110.25M (+6.9%)
|
-60.52M
est: -72.03M (+16.0%)
|
-45.74M
est: -23.54M (-94.3%)
|
-16.00M
est: 4.80M (-433.5%)
|
12.05M
est: -60.83M (+119.8%)
|
36.00M
est: 90.32M (-60.1%)
|
36.55M
est: 92.27M (-60.4%)
|
42.40M
est: 91.29M (-53.6%)
|
91.50M
91.50M – 91.50M
+0.2% YoY
|
90.26M
90.26M – 90.26M
-1.4% YoY
|
89.02M
88.61M – 89.44M
-1.4% YoY
|
87.79M
87.79M – 87.79M
-1.4% YoY
|
86.55M
86.55M – 86.55M
-1.4% YoY
|
| Net Income |
-292.00M
est: -397.70M (+26.6%)
|
-113.60M
est: -130.55M (+13.0%)
|
-75.60M
est: -90.26M (+16.2%)
|
-60.00M
est: -46.05M (-30.3%)
|
-29.13M
est: -42.54M (+31.5%)
|
2.0K
est: -146.58M (+100.0%)
|
21.59M
est: 9.22M (+134.2%)
|
30.28M
est: 15.35M (+97.2%)
|
31.11M
est: 27.86M (+11.7%)
|
12.80M
12.59M – 16.79M
-54.1% YoY
|
10.13M
9.98M – 10.28M
-20.9% YoY
|
6.08M
6.08M – 6.08M
-40.0% YoY
|
2.03M
2.03M – 2.03M
-66.7% YoY
|
-1.52M
-1.52M – -1.52M
-175.0% YoY
|
| SGA |
106.70M
est: 11.34M (+841.0%)
|
146.20M
est: 173.29M (-15.6%)
|
141.64M
est: 184.39M (-23.2%)
|
118.49M
est: 140.40M (-15.6%)
|
116.29M
est: 103.29M (+12.6%)
|
89.98M
est: 184.85M (-51.3%)
|
89.31M
est: 82.95M (+7.7%)
|
80.16M
est: 84.75M (-5.4%)
|
71.21M
est: 83.84M (-15.1%)
|
84.03M
84.03M – 84.03M
+0.2% YoY
|
82.90M
82.90M – 82.90M
-1.4% YoY
|
81.76M
81.38M – 82.14M
-1.4% YoY
|
80.63M
80.63M – 80.63M
-1.4% YoY
|
79.49M
79.49M – 79.49M
-1.4% YoY
|
| EPS |
-7.86
est: -8.10 (+3.0%)
|
-2.99
est: -2.97 (-0.5%)
|
-2.13
est: -2.16 (+1.3%)
|
-1.52
est: -1.41 (-8.2%)
|
-0.72
est: -0.87 (+16.9%)
|
0.02
est: 0.17 (-88.0%)
|
0.46
est: 0.18 (+152.7%)
|
0.62
est: 0.30 (+106.7%)
|
0.62
est: 0.55 (+12.7%)
|
0.29
0.25 – 0.33
-47.3% YoY
|
0.20
0.20 – 0.20
-31.0% YoY
|
0.12
0.12 – 0.12
-40.0% YoY
|
0.04
0.04 – 0.04
-66.7% YoY
|
-0.03
-0.03 – -0.03
-175.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-01 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
53.31M
OE per share TTM
1.05
Owner's Yield
14.44%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
37
Total invested
9.01M
Insider transactions (90d)
0
Beneficial owners (>5%)
44
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 3.83M | 7.80% | 3.69M | — | — | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 3.68M | 9.00% | — | 57.2K | 3.61M | 71.7K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 3 | Alger Associates, Inc. 13-3017981 | 3.42M | 8.59% | 3.42M | — | 3.42M | — | HC | New York | 2021-02-16 | ↗ |
| 4 | Alger Group Holdings, LLC | 3.42M | 8.59% | 3.42M | — | 3.42M | — | HC | New York | 2021-02-16 | ↗ |
| 5 | Anders Hove | 2.74M | 5.80% | — | 2.74M | — | — | IN | United States of America | 2023-09-01 | ↗ |
| 6 | James N. Topper | 2.63M | 5.40% | — | 2.63M | — | 2.63M | IN | Delaware | 2024-03-29 | ↗ |
| 7 | Patrick J. Heron | 2.63M | 5.40% | — | 2.63M | — | 2.63M | IN | Delaware | 2024-03-29 | ↗ |
| 8 | Israel A. Englander | 2.24M | 5.50% | — | 2.24M | — | 2.24M | IN | United States | 2022-01-14 | ↗ |
| 9 | Millennium Group Management LLC | 2.24M | 5.50% | — | 2.24M | — | 2.24M | OO | United States | 2022-01-14 | ↗ |
| 10 | Millennium Management LLC | 2.24M | 5.50% | — | 2.24M | — | 2.24M | OO | United States | 2022-01-14 | ↗ |
| 11 | GOLDMAN SACHS & CO. LLC | 2.10M | 5.10% | — | — | 13.00 | 2.10M | BD, IA, OO | Delaware | 2022-02-08 | ↗ |
| 12 | THE GOLDMAN SACHS GROUP, INC. | 2.10M | 5.10% | — | — | 13.00 | 2.10M | HC, CO | Delaware | 2022-02-08 | ↗ |
| 13 | Albert Cha | 1.93M | 4.00% | — | 1.93M | — | 1.93M | IN | Delaware | 2024-03-29 | ↗ |
| 14 | James Brush | 1.93M | 4.00% | — | 1.93M | — | 1.93M | IN | Delaware | 2024-03-29 | ↗ |
| 15 | Integrated Core Strategies (US) LLC | 1.76M | 4.30% | — | 1.76M | — | 1.76M | OO | — | 2021-11-19 | ↗ |
| 16 | Acorn Bioventures 2 L.P. | 1.59M | 3.30% | — | 1.59M | — | — | PN | Delaware | 2023-09-01 | ↗ |
| 17 | Acorn Capital Advisors GP 2, LLC | 1.59M | 3.30% | — | 1.59M | — | — | OO | Delaware | 2023-09-01 | ↗ |
| 18 | FHMLSP, L.L.C. | 1.30M | 2.70% | — | 1.30M | — | 1.30M | OO | Delaware | 2024-03-29 | ↗ |
| 19 | FHMLSP, L.P. | 1.30M | 2.70% | — | 1.30M | — | 1.30M | PN | Delaware | 2024-03-29 | ↗ |
| 20 | Frazier Life Sciences Public Fund, L.P. | 1.30M | 2.70% | — | 1.30M | — | 1.30M | PN | Delaware | 2024-03-29 | ↗ |
| 21 | Acorn Bioventures, L.P. | 1.15M | 2.40% | — | 1.15M | — | — | PN | Delaware | 2023-09-01 | ↗ |
| 22 | Acorn Capital Advisors GP, LLC | 1.15M | 2.40% | — | 1.15M | — | — | OO | Delaware | 2023-09-01 | ↗ |
| 23 | 13-3017981 | 890.4K | 2.18% | 890.4K | — | 890.4K | — | HC | New York | 2021-11-10 | ↗ |
| 24 | FHMLSP Overage, L.L.C. | 639.1K | 1.30% | — | 639.1K | — | 639.1K | OO | Delaware | 2024-03-29 | ↗ |
| 25 | FHMLSP Overage, L.P. | 639.1K | 1.30% | — | 639.1K | — | 639.1K | PN | Delaware | 2024-03-29 | ↗ |
| 26 | Frazier Life Sciences Public Overage Fund, L.P. | 639.1K | 1.30% | — | 639.1K | — | 639.1K | PN | Delaware | 2024-03-29 | ↗ |
| 27 | STATE STREET CORPORATION | 578.1K | 1.41% | — | 539.5K | — | 578.1K | HC | — | 2022-02-10 | ↗ |
| 28 | Daniel Estes | 453.4K | 0.90% | — | 453.4K | — | 453.4K | IN | Delaware | 2024-03-29 | ↗ |
| 29 | FHMLS XI, L.L.C. | 453.4K | 0.90% | — | 453.4K | — | 453.4K | OO | Delaware | 2024-03-29 | ↗ |
| 30 | FHMLS XI, L.P. | 453.4K | 0.90% | — | 453.4K | — | 453.4K | PN | Delaware | 2024-03-29 | ↗ |
| 31 | Frazier Life Sciences XI, L.P. | 453.4K | 0.90% | — | 453.4K | — | 453.4K | PN | Delaware | 2024-03-29 | ↗ |
| 32 | FHMLS X, L.L.C. | 244.2K | 0.50% | — | 244.2K | — | 244.2K | OO | Delaware | 2024-03-29 | ↗ |
| 33 | FHMLS X, L.P. | 244.2K | 0.50% | — | 244.2K | — | 244.2K | PN | Delaware | 2024-03-29 | ↗ |
| 34 | Frazier Life Sciences X, L.P. | 244.2K | 0.50% | — | 244.2K | — | 244.2K | PN | Delaware | 2024-03-29 | ↗ |
| 35 | Millennium International Management LP | 242.0K | 0.60% | — | 242.0K | — | 242.0K | PN | — | 2021-11-19 | ↗ |
| 36 | Integrated Assets II LLC | 219.0K | 0.50% | — | 219.0K | — | 219.0K | OO | — | 2021-11-19 | ↗ |
| 37 | ICS Opportunities, Ltd. | 18.8K | 0.00% | — | 18.8K | — | 18.8K | CO | — | 2021-11-19 | ↗ |
| 38 | Integrated Assets, Ltd. | 4.2K | 0.00% | — | 4.2K | — | 4.2K | CO | — | 2021-11-19 | ↗ |
| 39 | EcoR1 Capital, LLC | — | 11.00% | — | — | — | — | IA, OO | Delaware | 2021-02-12 | ↗ |
| 40 | Oleg Nodelman | — | 11.00% | — | — | — | — | HC, IN | Delaware | 2021-02-12 | ↗ |
| 41 | Company, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 42 | Deerfield Mgmt, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 43 | Deerfield Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 44 | James E. Flynn | — | 0.00% | — | — | — | — | IN | United States | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
37
-116 vs prev Q
New positions
6
Closed positions
121
Increased
20
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 89.4K +89.4K (+100.0%) | 531.70M +531.7M (+100.0%) | 0.18% +0.178 pp | 0.01% +0.009 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 61.3K +61.3K (+100.0%) | 364.00M +364.0M (+100.0%) | 0.12% +0.122 pp | 0.00% +0.001 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 3 | ACORN CAPITAL ADVISORS, LLC | 4.13M +— (+0.0%) | 24.58M +2.6M (+12.1%) | 8.21% -0.106 pp | 8.33% -2.807 pp | USD3.07 +93.8% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 3.80M +106.0K (+2.9%) | 22.60M +3.0M (+15.3%) | 7.54% +0.116 pp | 0.00% +0.000 pp | USD34.89 -82.9% | 53 qtrs — |
| 5 | BLACKROCK, INC. | 3.64M +64.7K (+1.8%) | 21.67M +2.7M (+14.1%) | 7.24% +0.037 pp | 0.00% +0.000 pp | USD2.61 +128.0% | 6 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 2.12M -27.4K (-1.3%) | 12.64M +1.2M (+10.6%) | 4.22% -0.109 pp | 0.02% +0.005 pp | USD6.84 -13.0% | 29 qtrs — |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 2.02M -28.5K (-1.4%) | 12.04M +1.1M (+10.5%) | 4.02% -0.109 pp | 0.02% +0.001 pp | USD7.37 -19.3% | 28 qtrs — |
| 8 | AMERICAN CENTURY COMPANIES INC | 1.65M +166.9K (+11.3%) | 9.82M +1.9M (+24.7%) | 3.28% +0.294 pp | 0.00% +0.001 pp | USD4.05 +46.9% | 9 qtrs — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1.34M +67.7K (+5.3%) | 7.97M +1.2M (+18.1%) | 2.66% +0.102 pp | 0.00% +0.000 pp | USD3.69 +61.2% | 14 qtrs — |
| 10 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 1.12M +292.1K (+35.3%) | 6.67M +2.3M (+51.6%) | 2.23% +0.559 pp | 0.04% +0.011 pp | USD4.79 +24.2% | 9 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 994.3K +10.8K (+1.1%) | 5.92M +693.9K (+13.3%) | 1.98% -0.004 pp | 0.00% +0.000 pp | USD14.32 -58.4% | 53 qtrs — |
| 12 | STATE STREET CORP | 877.1K +128.4K (+17.2%) | 5.22M +1.2M (+31.3%) | 1.74% +0.236 pp | 0.00% +0.000 pp | USD6.68 -10.9% | 51 qtrs — |
| 13 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 875.3K -68.2K (-7.2%) | 5.21M +198.2K (+4.0%) | 1.74% -0.160 pp | 0.01% -0.002 pp | USD3.55 +67.6% | 17 qtrs — |
| 14 | KENNEDY CAPITAL MANAGEMENT LLC | 868.3K +685.0 (+0.1%) | 5.17M +559.4K (+12.1%) | 1.72% -0.021 pp | 0.11% +0.008 pp | USD2.77 +114.8% | 6 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 794.0K +559.3K (+238.4%) | 4.72M +3.5M (+279.2%) | 1.58% +1.105 pp | 0.00% +0.000 pp | USD5.53 +7.6% | 52 qtrs — |
| 16 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 773.5K +339.9K (+78.4%) | 4.60M +2.3M (+99.9%) | 1.54% +0.664 pp | 0.10% +0.047 pp | USD5.08 +17.1% | 17 qtrs — |
| 17 | RITHOLTZ WEALTH MANAGEMENT | 694.0K +223.2K (+47.4%) | 4.13M +1.6M (+65.2%) | 1.38% +0.431 pp | 0.08% +0.027 pp | USD4.98 +19.5% | 9 qtrs — |
| 18 | AQR CAPITAL MANAGEMENT LLC | 666.6K +535.9K (+410.1%) | 3.97M +3.3M (+471.6%) | 1.32% +1.061 pp | 0.00% +0.002 pp | USD5.42 +9.8% | 5 qtrs — |
| 19 | NORTHERN TRUST CORP | 616.2K +89.5K (+17.0%) | 3.67M +869.4K (+31.1%) | 1.22% +0.164 pp | 0.00% +0.000 pp | USD7.63 -22.0% | 51 qtrs — |
| 20 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 547.9K +83.1K (+17.9%) | 3.26M +792.0K (+32.1%) | 1.09% +0.153 pp | 0.00% +0.000 pp | USD3.55 +67.6% | 4 qtrs — |
| 21 | GLOBEFLEX CAPITAL L P | 452.6K +— (+0.0%) | 2.69M +289.7K (+12.1%) | 0.90% -0.012 pp | 0.41% +0.042 pp | USD6.98 -14.8% | 23 qtrs — |
| 22 | SEI INVESTMENTS CO | 429.9K +82.7K (+23.8%) | 2.56M +714.2K (+38.7%) | 0.85% +0.155 pp | 0.00% +0.001 pp | USD8.07 -26.3% | 34 qtrs — |
| 23 | LSV ASSET MANAGEMENT | 404.8K -155.1K (-27.7%) | 2.41M -564.0K (-19.0%) | 0.80% -0.323 pp | 0.01% -0.001 pp | USD3.45 +72.5% | 14 qtrs — |
| 24 | D. E. SHAW & CO., INC. | 378.3K -120.3K (-24.1%) | 2.25M -396.7K (-15.0%) | 0.75% -0.252 pp | 0.00% 0.000 pp | USD3.00 +98.3% | 6 qtrs — |
| 25 | BANK OF NEW YORK MELLON CORP | 351.9K -3.5K (-1.0%) | 2.09M +206.7K (+11.0%) | 0.70% -0.016 pp | 0.00% +0.000 pp | USD7.17 -17.0% | 53 qtrs — |
| 26 | MORGAN STANLEY | 326.8K -51.3K (-13.6%) | 1.94M -63.3K (-3.2%) | 0.65% -0.112 pp | 0.00% +0.000 pp | USD4.89 +21.7% | 51 qtrs — |
| 27 | PRUDENTIAL FINANCIAL INC | 286.5K +65.6K (+29.7%) | 1.70M +531.5K (+45.3%) | 0.57% +0.125 pp | 0.00% +0.001 pp | USD3.60 +65.3% | 13 qtrs — |
| 28 | RUSSELL INVESTMENTS GROUP, LTD. | 251.7K -713.0K (-73.9%) | 1.50M -3.6M (-70.8%) | 0.50% -1.441 pp | 0.00% -0.004 pp | USD5.31 +12.1% | 7 qtrs — |
| 29 | FEDERATED HERMES, INC. | 237.9K +39.9K (+20.1%) | 1.42M +364.0K (+34.6%) | 0.47% +0.074 pp | 0.00% +0.001 pp | USD10.64 -44.1% | 39 qtrs — |
| 30 | PANAGORA ASSET MANAGEMENT INC | 194.9K +29.0K (+17.5%) | 1.16M +278.5K (+31.6%) | 0.39% +0.053 pp | 0.00% +0.001 pp | USD4.67 +27.4% | 7 qtrs — |
| 31 | EMPOWERED FUNDS, LLC | 186.2K +66.6K (+55.7%) | 1.11M +472.9K (+74.5%) | 0.37% +0.129 pp | 0.01% +0.002 pp | USD5.15 +15.5% | 3 qtrs — |
| 32 | PROSPERA FINANCIAL SERVICES INC | 185.5K -4.1K (-2.2%) | 1.10M +96.8K (+9.6%) | 0.37% -0.013 pp | 0.02% +0.001 pp | USD4.30 +38.4% | 23 qtrs — |
| 33 | FRANKLIN RESOURCES INC | 182.7K +9.0K (+5.2%) | 1.09M +164.8K (+17.9%) | 0.36% +0.014 pp | 0.00% +0.000 pp | USD5.11 +16.4% | 6 qtrs — |
| 34 | FMR LLC | 163.9K +18.6K (+12.8%) | 975.0K +203.6K (+26.4%) | 0.33% +0.033 pp | 0.00% +0.000 pp | USD3.91 +52.2% | 16 qtrs — |
| 35 | CITADEL ADVISORS LLC | 162.7K +162.7K (+100.0%) | 967.9K +967.9K (+100.0%) | 0.32% +0.323 pp | 0.00% +0.000 pp | USD5.95 +0.0% | 37 qtrs — |
| 36 | TWO SIGMA INVESTMENTS, LP | 162.4K +106.2K (+189.3%) | 966.0K +668.0K (+224.1%) | 0.32% +0.210 pp | 0.00% +0.001 pp | USD4.99 +19.2% | 19 qtrs — |
| 37 | MACKENZIE FINANCIAL CORP | 161.0K -14.2K (-8.1%) | 965.5K +35.2K (+3.8%) | 0.32% -0.033 pp | 0.00% +0.000 pp | USD3.11 +91.3% | 5 qtrs — |
| 38 | LOS ANGELES CAPITAL MANAGEMENT LLC | 148.1K -125.9K (-45.9%) | 808.8K -646.4K (-44.4%) | 0.29% -0.257 pp | 0.00% -0.002 pp | USD2.78 +114.0% | 6 qtrs — |
| 39 | STATE OF WISCONSIN INVESTMENT BOARD | 133.8K +79.5K (+146.3%) | 796.0K +507.5K (+176.0%) | 0.27% +0.157 pp | 0.00% +0.001 pp | USD5.69 +4.6% | 2 qtrs — |
| 40 | UBS GROUP AG | 127.3K -248.8K (-66.1%) | 757.5K -1.2M (-62.1%) | 0.25% -0.504 pp | 0.00% 0.000 pp | USD3.66 +62.6% | 45 qtrs — |
| 41 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 125.4K +— (+0.0%) | 746.0K +80.2K (+12.1%) | 0.25% -0.003 pp | 0.00% +0.000 pp | USD3.42 +74.0% | 52 qtrs — |
| 42 | FIRST TRUST ADVISORS LP | 122.8K +3.0K (+2.5%) | 730.7K +94.6K (+14.9%) | 0.24% +0.003 pp | 0.00% +0.000 pp | USD5.33 +11.6% | 2 qtrs — |
| 43 | QUBE RESEARCH & TECHNOLOGIES LTD | 111.5K -44.0K (-28.3%) | 663.5K -162.2K (-19.6%) | 0.22% -0.091 pp | 0.00% 0.000 pp | USD4.98 +19.5% | 15 qtrs — |
| 44 | INVESCO LTD. | 108.3K +44.5K (+69.7%) | 644.4K +305.5K (+90.2%) | 0.22% +0.087 pp | 0.00% +0.000 pp | USD4.60 +29.3% | 7 qtrs — |
| 45 | STRS OHIO | 99.4K -25.5K (-20.4%) | 591.4K -71.8K (-10.8%) | 0.20% -0.054 pp | 0.00% 0.000 pp | USD3.14 +89.5% | 7 qtrs — |
| 46 | WINTON GROUP LTD | 97.2K +35.8K (+58.4%) | 578.1K +252.5K (+77.5%) | 0.19% +0.070 pp | 0.02% +0.008 pp | USD5.55 +7.2% | 2 qtrs — |
| 47 | EVERGREEN CAPITAL MANAGEMENT LLC | 96.0K +— (+0.0%) | 571.2K +61.4K (+12.1%) | 0.19% -0.003 pp | 0.01% +0.001 pp | USD3.43 +73.5% | 3 qtrs — |
| 48 | ROUND ROCK ADVISORS, LLC | 105.0K +39.6K (+60.6%) | 570.0K +240.4K (+72.9%) | 0.21% +0.077 pp | 0.09% +0.034 pp | USD5.55 +7.2% | 2 qtrs — |
| 49 | HAVEN PRIVATE, LLC | 92.1K +92.1K (+100.0%) | 547.9K +547.9K (+100.0%) | 0.18% +0.183 pp | 0.24% +0.240 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 50 | BARCLAYS PLC | 81.4K +3.4K (+4.4%) | 484.5K +285.6K (+143.5%) | 0.16% +0.005 pp | 0.00% +0.000 pp | USD4.44 +34.0% | 51 qtrs — |
| 51 | NUVEEN, LLC | 79.1K +— (+0.0%) | 470.7K +50.6K (+12.1%) | 0.16% -0.002 pp | 0.00% +0.000 pp | USD2.96 +101.0% | 4 qtrs — |
| 52 | CANADA PENSION PLAN INVESTMENT BOARD | 75.2K +75.2K (+100.0%) | 447.4K +447.4K (+100.0%) | 0.15% +0.149 pp | 0.00% +0.000 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 53 | TWO SIGMA ADVISERS, LP | 71.1K -2.1K (-2.9%) | 423.0K +34.4K (+8.8%) | 0.14% -0.006 pp | 0.00% +0.000 pp | USD3.51 +69.5% | 20 qtrs — |
| 54 | LAZARD ASSET MANAGEMENT LLC | 59.6K -3.6K (-5.7%) | 354.5K +19.2K (+5.7%) | 0.12% -0.009 pp | 0.00% +0.000 pp | USD5.31 +12.1% | 9 qtrs — |
| 55 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 59.3K +8.5K (+16.7%) | 353.0K +83.0K (+30.7%) | 0.12% +0.016 pp | 0.00% +0.000 pp | USD5.40 +10.2% | 2 qtrs — |
| 56 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 57.1K -35.7K (-38.5%) | 339.7K -153.0K (-31.1%) | 0.11% -0.073 pp | 0.00% +0.000 pp | USD4.87 +22.2% | 3 qtrs — |
| 57 | VERDAD ADVISERS, LP | 55.5K +55.5K (+100.0%) | 330.5K +330.5K (+100.0%) | 0.11% +0.110 pp | 0.38% +0.378 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 58 | RHUMBLINE ADVISERS | 53.9K -6.1K (-10.2%) | 320.7K +2.1K (+0.6%) | 0.11% -0.014 pp | 0.00% +0.000 pp | USD3.34 +78.1% | 11 qtrs — |
| 59 | STATE OF WYOMING | 53.2K +40.4K (+317.3%) | 316.3K +248.6K (+367.6%) | 0.11% +0.080 pp | 0.03% +0.027 pp | USD5.80 +2.6% | 2 qtrs — |
| 60 | BANK OF AMERICA CORP /DE/ | 52.4K +7.4K (+16.5%) | 311.7K +72.9K (+30.5%) | 0.10% +0.014 pp | 0.00% +0.000 pp | USD3.69 +61.2% | 52 qtrs — |
| 61 | D'ORAZIO & ASSOCIATES, INC. | 49.8K +17.9K (+56.0%) | 296.4K +126.8K (+74.8%) | 0.10% +0.035 pp | 0.04% +0.016 pp | USD4.97 +19.7% | 3 qtrs — |
| 62 | WELLS FARGO & COMPANY/MN | 48.3K +15.8K (+48.4%) | 287.3K +114.5K (+66.3%) | 0.10% +0.031 pp | 0.00% +0.000 pp | USD4.71 +26.3% | 51 qtrs — |
| 63 | MAN GROUP PLC | 47.3K +47.3K (+100.0%) | 281.6K +281.6K (+100.0%) | 0.09% +0.094 pp | 0.00% +0.001 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 64 | VIRTUS ETF ADVISERS LLC | 47.2K +— (+0.0%) | 280.7K +30.2K (+12.1%) | 0.09% -0.001 pp | 0.13% -0.005 pp | USD2.96 +101.0% | 4 qtrs — |
| 65 | METIS GLOBAL PARTNERS, LLC | 42.6K -13.2K (-23.7%) | 253.4K -42.9K (-14.5%) | 0.08% -0.028 pp | 0.01% -0.001 pp | USD4.71 +26.3% | 8 qtrs — |
| 66 | LPL FINANCIAL LLC | 40.4K -10.9K (-21.2%) | 240.6K -31.8K (-11.7%) | 0.08% -0.023 pp | 0.00% +0.000 pp | USD3.76 +58.2% | 9 qtrs — |
| 67 | VISE TECHNOLOGIES, INC. | 40.3K +40.3K (+100.0%) | 239.8K +239.8K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.005 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 68 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 39.3K -159.2K (-80.2%) | 233.9K -820.2K (-77.8%) | 0.08% -0.321 pp | 0.00% -0.001 pp | USD4.84 +22.9% | 4 qtrs — |
| 69 | JANE STREET GROUP, LLC | 36.4K -102.2K (-73.8%) | 216.4K -519.3K (-70.6%) | 0.07% -0.207 pp | 0.00% 0.000 pp | USD4.77 +24.7% | 9 qtrs — |
| 70 | BARON WEALTH MANAGEMENT LLC | 35.4K +13.6K (+62.6%) | 210.6K +95.0K (+82.2%) | 0.07% +0.027 pp | 0.06% +0.027 pp | USD5.56 +7.0% | 2 qtrs — |
| 71 | ENTRYPOINT CAPITAL, LLC | 35.4K +35.4K (+100.0%) | 210.6K +210.6K (+100.0%) | 0.07% +0.070 pp | 0.08% +0.082 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 72 | DIADEMA PARTNERS LP | 33.8K -102.1K (-75.1%) | 201.1K -520.5K (-72.1%) | 0.07% -0.206 pp | 0.03% -0.150 pp | USD5.31 +12.1% | 2 qtrs — |
| 73 | PRELUDE CAPITAL MANAGEMENT, LLC | 32.1K -6.3K (-16.3%) | 191.3K -12.7K (-6.2%) | 0.06% -0.013 pp | 0.01% -0.002 pp | USD3.32 +79.2% | 5 qtrs — |
| 74 | STOKES FAMILY OFFICE, LLC | 28.1K +28.1K (+100.0%) | 167.1K +167.1K (+100.0%) | 0.06% +0.056 pp | 0.02% +0.015 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 75 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 27.3K +27.3K (+100.0%) | 162.6K +162.6K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD5.95 +0.0% | 3 qtrs — |
| 76 | KATHMERE CAPITAL MANAGEMENT, LLC | 27.1K -822.0 (-2.9%) | 161.4K +13.0K (+8.8%) | 0.05% -0.002 pp | 0.01% +0.000 pp | USD3.95 +50.6% | 3 qtrs — |
| 77 | PRICE T ROWE ASSOCIATES INC /MD/ | 25.9K +4.3K (+19.9%) | 155.0K +40.0K (+34.8%) | 0.05% +0.008 pp | 0.00% +0.000 pp | USD3.45 +72.5% | 6 qtrs — |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 24.4K +9.9K (+67.8%) | 145.3K +68.0K (+88.1%) | 0.05% +0.019 pp | 0.00% +0.000 pp | USD4.17 +42.7% | 4 qtrs — |
| 79 | C2C WEALTH MANAGEMENT, LLC | 23.0K +— (+0.0%) | 137.0K +14.7K (+12.1%) | 0.05% -0.001 pp | 0.12% +0.011 pp | USD3.36 +77.1% | 5 qtrs — |
| 80 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 21.8K +21.8K (+100.0%) | 129.7K +129.7K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.001 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 81 | JPMORGAN CHASE & CO | 21.1K +3.8K (+22.1%) | 125.6K +33.8K (+36.8%) | 0.04% +0.007 pp | 0.00% +0.000 pp | USD3.64 +63.5% | 51 qtrs — |
| 82 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 20.2K -64.0 (-0.3%) | 119.9K +12.6K (+11.7%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD2.59 +129.7% | 6 qtrs — |
| 83 | HERON BAY CAPITAL MANAGEMENT | 20.1K +20.1K (+100.0%) | 119.3K +119.3K (+100.0%) | 0.04% +0.040 pp | 0.02% +0.023 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 84 | ONE WEALTH ADVISORS, LLC | 19.4K +19.4K (+100.0%) | 115.4K +115.4K (+100.0%) | 0.04% +0.039 pp | 0.01% +0.014 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 85 | INTECH INVESTMENT MANAGEMENT LLC | 18.9K +— (+0.0%) | 112.5K +12.1K (+12.1%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD3.02 +97.0% | 5 qtrs — |
| 86 | ENGINEERS GATE MANAGER LP | 18.8K +18.8K (+100.0%) | 111.8K +111.8K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.001 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 87 | MILLENNIUM MANAGEMENT LLC | 16.6K -89.0K (-84.3%) | 98.9K -462.1K (-82.4%) | 0.03% -0.180 pp | 0.00% 0.000 pp | USD5.95 +0.0% | 52 qtrs — |
| 88 | AXQ CAPITAL, LP | 16.6K +16.6K (+100.0%) | 98.7K +98.7K (+100.0%) | 0.03% +0.033 pp | 0.02% +0.022 pp | USD5.95 +0.0% | 1 qtrs NEW |
| 89 | CAPROCK GROUP, LLC | 16.4K +4.7K (+39.8%) | 97.9K +38.6K (+65.0%) | 0.03% +0.009 pp | 0.00% +0.001 pp | USD5.49 +8.4% | 2 qtrs — |
| 90 | HEADLANDS TECHNOLOGIES LLC | 16.0K -13.2K (-45.2%) | 95.1K -59.9K (-38.6%) | 0.03% -0.027 pp | 0.01% -0.004 pp | USD5.19 +14.6% | 4 qtrs — |
| 91 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 15.7K +7.4K (+88.9%) | 93.5K +49.3K (+111.6%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD4.41 +34.9% | 5 qtrs — |
| 92 | ALLIANCEBERNSTEIN L.P. | 13.8K +— (+0.0%) | 82.1K +8.8K (+12.1%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD3.43 +73.5% | 3 qtrs — |
| 93 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 13.4K -1.7K (-11.4%) | 79.9K -593.0 (-0.7%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD2.96 +101.0% | 4 qtrs — |
| 94 | CAUSEWAY CAPITAL MANAGEMENT LLC | 13.3K -785.0 (-5.6%) | 79.2K +4.4K (+5.8%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD2.96 +101.0% | 4 qtrs — |
| 95 | CWM, LLC | 12.8K +3.9K (+43.6%) | 76.0K +29.0K (+61.7%) | 0.03% +0.008 pp | 0.00% +0.000 pp | USD4.10 +45.1% | 7 qtrs — |
| 96 | PERKINS CAPITAL MANAGEMENT INC | 12.5K +300.0 (+2.5%) | 74.4K +9.6K (+14.8%) | 0.02% +0.000 pp | 0.06% +0.002 pp | USD5.33 +11.6% | 2 qtrs — |
| 97 | ADVISOR GROUP HOLDINGS, INC. | 12.2K -6.1K (-33.4%) | 72.4K -23.6K (-24.6%) | 0.02% -0.013 pp | 0.00% +0.000 pp | USD3.07 +93.8% | 24 qtrs — |
| 98 | CERITY PARTNERS LLC | 12.1K +1.9K (+18.2%) | 71.8K +17.6K (+32.5%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD3.82 +55.8% | 3 qtrs — |
| 99 | PFG INVESTMENTS, LLC | 12.0K -3.0K (-20.0%) | 71.4K -8.3K (-10.4%) | 0.02% -0.006 pp | 0.00% -0.001 pp | USD2.96 +101.0% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Hartford Multifactor Small Cap ETF ROSC | 0.71% | 436.7K | 0.34% |
| 2 | Invesco Dorsey Wright SmallCap Momentum ETF DWAS | 0.41% | 1.93M | 0.60% |
| 3 | First Trust Dow Jones Select MicroCap Index Fund FDM | 0.40% | 1.04M | 0.65% |
| 4 | Royce Quant Small-Cap Quality Value ETF SQLV | 0.27% | 79.0K | 0.60% |
| 5 | Applied Finance IVS US SMID ETF IVSS | 0.09% | 11.0K | 0.59% |
| 6 | iShares Micro-Cap ETF IWC | 0.08% | 1.18M | 0.60% |
| 7 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.08% | 1.29M | 0.47% |
| 8 | WisdomTree U.S. SmallCap Fund EES | 0.07% | 501.1K | 0.38% |
| 9 | Avantis U.S. Small Cap Value ETF AVUV | 0.06% | 16.56M | 0.25% |
| 10 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.05% | 573.5K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
6
Shares acquired
620.2K
Shares disposed
54.9K
Cash buys
—
Cash sales
6.00
Net activity
+565,365
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | NOUGUES MAXIMO F | Officer | A-Award | A | Common Stock | 46,739 | 0.00 | — | 240,023 | D | ↗ |
| 2026-02-18 | HUNT DOUGLAS M | Officer | A-Award | A | Common Stock | 49,394 | 0.00 | — | 205,301 | D | ↗ |
| 2026-02-18 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Common Stock | 159,778 | 0.00 | — | 7,305,729 | D | ↗ |
| 2026-01-07 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 6,405 | 5.88 | 37.7K | 193,284 | D | ↗ |
| 2026-01-07 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 5,014 | 5.88 | 29.5K | 155,907 | D | ↗ |
| 2026-01-07 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 18,012 | 5.88 | 105.9K | 7,145,951 | D | ↗ |
| 2026-01-06 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 4,540 | 5.84 | 26.5K | 199,689 | D | ↗ |
| 2026-01-06 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 3,973 | 5.84 | 23.2K | 160,921 | D | ↗ |
| 2026-01-06 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 16,938 | 5.84 | 99.0K | 7,163,963 | D | ↗ |
| 2025-11-11 | MILLER MICHAEL PATRICK | Director | S-Sale | D | Common Stock | 20,000 | 4.86 | 97.2K | 54,000 | D | ↗ |
| 2025-07-18 | Cesano Alessandra | Director | S-Sale | D | Common Stock | 27,000 | 3.37 | 90.9K | 41,850 | D | ↗ |
| 2025-07-09 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 3,935 | 3.54 | 13.9K | 204,229 | D | ↗ |
| 2025-07-09 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 3,443 | 3.54 | 12.2K | 164,894 | D | ↗ |
| 2025-07-09 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 21,580 | 3.54 | 76.3K | 7,180,901 | D | ↗ |
| 2025-07-08 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 5,587 | 3.53 | 19.7K | 208,164 | D | ↗ |
| 2025-07-08 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 4,374 | 3.53 | 15.5K | 168,337 | D | ↗ |
| 2025-07-08 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 25,592 | 3.53 | 90.4K | 7,202,481 | D | ↗ |
| 2025-06-13 | WILSON TROY EDWARD | Director | S-Sale | D | Common Stock | 10,800 | 3.40 | 36.7K | 43,550 | D | ↗ |
| 2025-06-13 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 8,100 | 3.39 | 27.5K | 94,958 | D | ↗ |
| 2025-06-13 | Senderowicz Adrian | Director | S-Sale | D | Common Stock | 27,000 | 3.40 | 91.8K | 27,000 | D | ↗ |
| 2025-06-13 | MOYES JAY M | Director | S-Sale | D | Common Stock | 22,000 | 3.40 | 74.8K | 53,322 | D | ↗ |
| 2025-06-13 | Dorval Allison | Director | S-Sale | D | Common Stock | 11,610 | 3.40 | 39.5K | 75,390 | D | ↗ |
| 2025-06-13 | Cesano Alessandra | Director | S-Sale | D | Common Stock | 12,150 | 3.40 | 41.3K | 68,850 | D | ↗ |
| 2025-06-11 | WILSON TROY EDWARD | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 54,350 | D | ↗ |
| 2025-06-11 | Stuglik Brian M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 103,058 | D | ↗ |
| 2025-06-11 | Senderowicz Adrian | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 54,000 | D | ↗ |
| 2025-06-11 | MOYES JAY M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 75,322 | D | ↗ |
| 2025-06-11 | MILLER MICHAEL PATRICK | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 74,000 | D | ↗ |
| 2025-06-11 | Dorval Allison | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 87,000 | D | ↗ |
| 2025-06-11 | Cesano Alessandra | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 81,000 | D | ↗ |
| 2025-02-07 | NOUGUES MAXIMO F | Officer | A-Award | A | Stock Option (Right to Buy) | 85,067 | 2.78 | 236.5K | 85,067 | D | ↗ |
| 2025-02-07 | Ludwig Jeffrey Jerome | Officer | A-Award | A | Common Stock | 47,841 | 0.00 | — | 156,792 | D | ↗ |
| 2025-02-07 | HUNT DOUGLAS M | Officer | A-Award | A | Common Stock | 48,117 | 0.00 | — | 172,711 | D | ↗ |
| 2025-02-07 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 274,622 | 2.78 | 763.4K | 274,622 | D | ↗ |
| 2025-01-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 10,227 | 3.15 | 32.2K | 152,295 | D | ↗ |
| 2025-01-02 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 9,437 | 3.15 | 29.7K | 108,951 | D | ↗ |
| 2025-01-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 8,633 | 3.15 | 27.2K | 124,594 | D | ↗ |
| 2025-01-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 33,841 | 3.15 | 106.7K | 7,029,674 | D | ↗ |
| 2024-08-12 | MILLER MICHAEL PATRICK | Director | S-Sale | D | Common Stock | 23,358 | 3.49 | 81.5K | 47,000 | — | ↗ |
| 2024-07-17 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 4,156 | 3.70 | 15.4K | 162,522 | — | ↗ |
| 2024-07-17 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 2,598 | 3.70 | 9.6K | 118,388 | — | ↗ |
| 2024-07-17 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 3,637 | 3.70 | 13.5K | 133,227 | — | ↗ |
| 2024-07-17 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 21,920 | 3.70 | 81.1K | 7,063,515 | — | ↗ |
| 2024-07-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 5,295 | 3.27 | 17.3K | 166,678 | — | ↗ |
| 2024-07-02 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 6,051 | 3.27 | 19.8K | 120,986 | — | ↗ |
| 2024-07-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 4,349 | 3.27 | 14.2K | 136,864 | — | ↗ |
| 2024-07-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 18,885 | 3.27 | 61.7K | 7,085,435 | — | ↗ |
| 2024-06-18 | WILSON TROY EDWARD | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 27,350 | — | ↗ |
| 2024-06-18 | Stuglik Brian M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 76,058 | — | ↗ |
| 2024-06-18 | Senderowicz Adrian | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 27,000 | — | ↗ |
| 2024-06-18 | MOYES JAY M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 48,322 | — | ↗ |
| 2024-06-18 | MILLER MICHAEL PATRICK | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 95,358 | — | ↗ |
| 2024-06-18 | Dorval Allison | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 60,000 | — | ↗ |
| 2024-06-18 | Cesano Alessandra | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 54,000 | — | ↗ |
| 2024-06-13 | WILSON TROY EDWARD | Director | S-Sale | D | Common Stock | 27,000 | 3.33 | 89.9K | 350 | — | ↗ |
| 2024-06-13 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 9,900 | 3.39 | 33.5K | 49,058 | — | ↗ |
| 2024-06-13 | Senderowicz Adrian | Director | S-Sale | D | Common Stock | 27,000 | 3.33 | 89.8K | 0 | — | ↗ |
| 2024-06-13 | MOYES JAY M | Director | S-Sale | D | Common Stock | 22,000 | 3.34 | 73.5K | 21,322 | — | ↗ |
| 2024-06-13 | Dorval Allison | Director | S-Sale | D | Common Stock | 11,000 | 3.37 | 37.1K | 33,000 | — | ↗ |
| 2024-03-15 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Common Stock | 6,577 | 0.00 | — | 7,104,320 | — | ↗ |
| 2024-02-12 | Wong Alvin F | Officer | A-Award | A | Stock Option (Right to Buy) | 59,946 | 6.36 | 381.3K | 59,946 | — | ↗ |
| 2024-02-12 | NOUGUES MAXIMO F | Officer | A-Award | A | Common Stock | 43,307 | 0.00 | — | 171,973 | — | ↗ |
| 2024-02-12 | Ludwig Jeffrey Jerome | Officer | A-Award | A | Stock Option (Right to Buy) | 37,466 | 6.36 | 238.3K | 37,466 | — | ↗ |
| 2024-02-12 | HUNT DOUGLAS M | Officer | A-Award | A | Stock Option (Right to Buy) | 52,452 | 6.36 | 333.6K | 52,452 | — | ↗ |
| 2024-02-12 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 222,573 | 6.36 | 1.42M | 222,573 | — | ↗ |
| 2024-01-03 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 7,733 | 4.49 | 34.7K | 98,214 | — | ↗ |
| 2024-01-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 15,682 | 4.49 | 70.3K | 128,666 | — | ↗ |
| 2024-01-03 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 12,956 | 4.49 | 58.1K | 99,970 | — | ↗ |
| 2024-01-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 8,358 | 4.49 | 37.5K | 103,319 | — | ↗ |
| 2024-01-03 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 41,396 | 4.49 | 185.7K | 6,936,947 | — | ↗ |
| 2023-12-04 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 280 | 3.76 | 1.1K | 97,934 | — | ↗ |
| 2023-11-07 | MILLER MICHAEL PATRICK | Director | S-Sale | D | Common Stock | 25,000 | 2.83 | 70.8K | 43,358 | — | ↗ |
| 2023-07-03 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 6,938 | 3.31 | 23.0K | 105,947 | — | ↗ |
| 2023-07-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 14,680 | 3.31 | 48.6K | 144,348 | — | ↗ |
| 2023-07-03 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 12,103 | 3.31 | 40.1K | 112,926 | — | ↗ |
| 2023-07-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 7,809 | 3.31 | 25.9K | 111,677 | — | ↗ |
| 2023-07-03 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 60,698 | 3.31 | 201.0K | 6,978,343 | — | ↗ |
| 2023-06-13 | WILSON TROY EDWARD | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 27,350 | — | ↗ |
| 2023-06-13 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 9,900 | 3.46 | 34.3K | 31,958 | — | ↗ |
| 2023-06-13 | Senderowicz Adrian | Director | S-Sale | D | Common Stock | 27,000 | 3.45 | 93.3K | 0 | — | ↗ |
| 2023-06-13 | MOYES JAY M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 43,322 | — | ↗ |
| 2023-06-13 | MILLER MICHAEL PATRICK | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 68,358 | — | ↗ |
| 2023-06-13 | Dorval Allison | Director | S-Sale | D | Common Stock | 10,000 | 3.45 | 34.5K | 17,000 | — | ↗ |
| 2023-06-13 | Cesano Alessandra | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 27,000 | — | ↗ |
| 2023-06-02 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 269 | 3.45 | 928.00 | 112,885 | — | ↗ |
| 2023-02-10 | Wong Alvin F | Officer | A-Award | A | Stock Option (Right to Buy) | 81,399 | 4.39 | 357.3K | 81,399 | — | ↗ |
| 2023-02-10 | NOUGUES MAXIMO F | Officer | A-Award | A | Stock Option (Right to Buy) | 81,399 | 4.39 | 357.3K | 81,399 | — | ↗ |
| 2023-02-10 | Ludwig Jeffrey Jerome | Officer | A-Award | A | Stock Option (Right to Buy) | 93,028 | 4.39 | 408.4K | 93,028 | — | ↗ |
| 2023-02-10 | HUNT DOUGLAS M | Officer | A-Award | A | Stock Option (Right to Buy) | 66,864 | 4.39 | 293.5K | 66,864 | — | ↗ |
| 2023-02-10 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Common Stock | 186,403 | 0.00 | — | 7,039,041 | — | ↗ |
| 2023-01-03 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 3,460 | 4.18 | 14.5K | 54,553 | — | ↗ |
| 2023-01-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 10,499 | 4.18 | 43.9K | 100,427 | — | ↗ |
| 2023-01-03 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 6,568 | 4.18 | 27.4K | 58,057 | — | ↗ |
| 2023-01-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 4,225 | 4.18 | 17.7K | 71,350 | — | ↗ |
| 2023-01-03 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 27,241 | 4.18 | 113.8K | 6,852,638 | — | ↗ |
| 2022-12-12 | AUERBACH ALAN H | Officer | A-Award | A | Common Stock | 568,181 | 4.40 | 2.50M | 6,879,879 | — | ↗ |
| 2022-12-02 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 514 | 4.50 | 2.3K | 58,013 | — | ↗ |
| 2022-12-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 159 | 4.50 | 715.15 | 110,926 | — | ↗ |
| 2022-12-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 429 | 4.50 | 1.9K | 75,575 | — | ↗ |
| 2022-12-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,251 | 4.50 | 5.6K | 6,311,698 | — | ↗ |
| 2022-11-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 163 | 2.25 | 366.75 | 111,085 | — | ↗ |
| 2022-11-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 429 | 2.25 | 965.25 | 76,004 | — | ↗ |
| 2022-11-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,242 | 2.25 | 2.8K | 6,312,949 | — | ↗ |
| 2022-10-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 165 | 2.34 | 385.34 | 111,248 | — | ↗ |
| 2022-10-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 435 | 2.34 | 1.0K | 76,433 | — | ↗ |
| 2022-10-03 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,260 | 2.34 | 2.9K | 6,314,191 | — | ↗ |
| 2022-09-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 164 | 2.59 | 424.69 | 111,413 | — | ↗ |
| 2022-09-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 433 | 2.59 | 1.1K | 76,868 | — | ↗ |
| 2022-09-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,254 | 2.59 | 3.2K | 6,315,451 | — | ↗ |
| 2022-08-09 | MILLER MICHAEL PATRICK | Director | S-Sale | D | Common Stock | 25,000 | 3.55 | 88.8K | 54,858 | — | ↗ |
| 2022-08-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 161 | 2.89 | 465.29 | 111,577 | — | ↗ |
| 2022-08-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 429 | 2.89 | 1.2K | 77,301 | — | ↗ |
| 2022-08-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,247 | 2.89 | 3.6K | 6,316,705 | — | ↗ |
| 2022-07-29 | Cesano Alessandra | Director | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 100,000 | 2.93 | 293.0K | 100,000 | — | ↗ |
| 2022-07-05 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 2,920 | 2.63 | 7.7K | 58,527 | — | ↗ |
| 2022-07-05 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 5,835 | 2.63 | 15.4K | 64,625 | — | ↗ |
| 2022-07-05 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 5,835 | 2.63 | 15.4K | 64,625 | — | ↗ |
| 2022-07-05 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 3,753 | 2.63 | 9.9K | 77,730 | — | ↗ |
| 2022-07-05 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 26,140 | 2.63 | 68.8K | 6,317,952 | — | ↗ |
| 2022-06-16 | WILSON TROY EDWARD | Director | S-Sale | D | Common Stock | 27,858 | 2.58 | 72.0K | 27,350 | — | ↗ |
| 2022-06-16 | Stuglik Brian M | Director | S-Sale | D | Common Stock | 13,000 | 2.69 | 34.9K | 41,858 | — | ↗ |
| 2022-06-16 | Senderowicz Adrian | Director | S-Sale | D | Common Stock | 27,858 | 2.63 | 73.3K | 27,000 | — | ↗ |
| 2022-06-16 | MOYES JAY M | Director | S-Sale | D | Common Stock | 22,858 | 2.64 | 60.4K | 38,322 | — | ↗ |
| 2022-06-14 | WILSON TROY EDWARD | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 55,208 | — | ↗ |
| 2022-06-14 | Stuglik Brian M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 54,858 | — | ↗ |
| 2022-06-14 | Senderowicz Adrian | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 54,858 | — | ↗ |
| 2022-06-14 | MOYES JAY M | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 61,180 | — | ↗ |
| 2022-06-14 | MILLER MICHAEL PATRICK | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 79,858 | — | ↗ |
| 2022-06-14 | Dorval Allison | Director | A-Award | A | Common Stock | 27,000 | 0.00 | — | 27,000 | — | ↗ |
| 2022-06-02 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 587 | 1.92 | 1.1K | 61,447 | — | ↗ |
| 2022-06-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 162 | 1.92 | 311.33 | 121,066 | — | ↗ |
| 2022-06-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 417 | 1.94 | 810.69 | 81,483 | — | ↗ |
| 2022-06-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,200 | 1.94 | 2.3K | 6,344,092 | — | ↗ |
| 2022-05-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 165 | 2.34 | 386.12 | 121,228 | — | ↗ |
| 2022-05-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 438 | 2.31 | 1.0K | 81,900 | — | ↗ |
| 2022-05-03 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,263 | 2.32 | 2.9K | 6,345,292 | — | ↗ |
| 2022-04-04 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 206 | 3.08 | 634.07 | 121,393 | — | ↗ |
| 2022-04-04 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 413 | 3.08 | 1.3K | 82,338 | — | ↗ |
| 2022-04-04 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,198 | 3.08 | 3.7K | 6,346,555 | — | ↗ |
| 2022-03-16 | MILLER MICHAEL PATRICK | Director | S-Sale | D | Common Stock | 25,653 | 2.80 | 71.8K | 52,858 | — | ↗ |
| 2022-03-03 | Wong Alvin F | Officer | A-Award | A | Stock Option (Right to Buy) | 64,118 | 0.00 | — | 64,118 | — | ↗ |
| 2022-03-03 | NOUGUES MAXIMO F | Officer | A-Award | A | Stock Option (Right to Buy) | 88,824 | 0.00 | — | 88,824 | — | ↗ |
| 2022-03-03 | Ludwig Jeffrey Jerome | Officer | A-Award | A | Stock Option (Right to Buy) | 55,882 | 2.33 | 130.2K | 55,882 | — | ↗ |
| 2022-03-03 | HUNT DOUGLAS M | Officer | A-Award | A | Common Stock | 22,647 | 0.00 | — | 82,751 | — | ↗ |
| 2022-03-03 | AUERBACH ALAN H | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 241,176 | 2.33 | 561.9K | 241,176 | — | ↗ |
| 2022-03-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 169 | 2.26 | 382.28 | 59,423 | — | ↗ |
| 2022-03-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 446 | 2.26 | 1.0K | 60,104 | — | ↗ |
| 2022-03-02 | AUERBACH ALAN H | Officer | S-Sale | D | Common Stock | 1,294 | 2.26 | 2.9K | 4,386,815 | — | ↗ |
| 2022-02-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 199 | 2.48 | 493.96 | 59,592 | — | ↗ |
| 2022-02-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 533 | 2.47 | 1.3K | 60,550 | — | ↗ |
| 2022-02-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,316 | 2.46 | 3.2K | 4,388,109 | — | ↗ |
| 2022-01-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 7,484 | 3.19 | 23.9K | 59,791 | — | ↗ |
| 2022-01-03 | Ludwig Jeffrey Jerome | Officer | S-Sale | D | Common Stock | 4,727 | 3.20 | 15.1K | 31,342 | — | ↗ |
| 2022-01-03 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 3,707 | 3.21 | 11.9K | 61,083 | — | ↗ |
| 2022-01-03 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 22,875 | 3.19 | 72.9K | 4,389,425 | — | ↗ |
| 2021-12-02 | Wong Alvin F | Officer | S-Sale | D | Common Stock | 1,131 | 2.91 | 3.3K | 17,152 | — | ↗ |
| 2021-12-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 162 | 2.95 | 477.90 | 67,275 | — | ↗ |
| 2021-12-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 441 | 2.90 | 1.3K | 64,790 | — | ↗ |
| 2021-12-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,837 | 2.90 | 5.3K | 4,412,300 | — | ↗ |
| 2021-11-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 156 | 5.67 | 884.68 | 67,437 | — | ↗ |
| 2021-11-02 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 427 | 5.64 | 2.4K | 65,231 | — | ↗ |
| 2021-11-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,795 | 5.63 | 10.1K | 4,414,137 | — | ↗ |
| 2021-10-04 | NOUGUES MAXIMO F | Officer | S-Sale | D | Common Stock | 161 | 6.20 | 998.22 | 67,593 | — | ↗ |
| 2021-10-04 | HUNT DOUGLAS M | Officer | S-Sale | D | Common Stock | 443 | 6.15 | 2.7K | 65,658 | — | ↗ |
| 2021-10-04 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,858 | 6.15 | 11.4K | 4,415,932 | — | ↗ |
| 2021-09-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 155 | 7.51 | 1.2K | 67,754 | — | ↗ |
| 2021-09-02 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 422 | 7.52 | 3.2K | 66,101 | — | ↗ |
| 2021-09-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 1,764 | 7.60 | 13.4K | 4,417,790 | — | ↗ |
| 2021-08-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 154 | 7.54 | 1.2K | 67,909 | — | ↗ |
| 2021-08-02 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 420 | 7.53 | 3.2K | 66,523 | — | ↗ |
| 2021-08-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 1,764 | 7.53 | 13.3K | 4,419,554 | — | ↗ |
| 2021-07-15 | Dorval Allison | Director | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 108,721 | 8.19 | 890.4K | 108,721 | — | ↗ |
| 2021-07-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 155 | 9.26 | 1.4K | 68,063 | — | ↗ |
| 2021-07-02 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 1,016 | 9.15 | 9.3K | 66,943 | — | ↗ |
| 2021-07-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 5,332 | 8.84 | 47.1K | 4,421,318 | — | ↗ |
| 2021-06-17 | Wong Alvin F | Officer | A-Award | A | STOCK OPTION (RIGHT TO BUY) | 90,000 | 10.21 | 918.9K | 90,000 | — | ↗ |
| 2021-06-15 | Wong Alvin F | Officer | — | D | STOCK OPTION (RIGHT TO BUY) | 10,500 | 39.50 | 414.8K | 0 | — | ↗ |
| 2021-06-15 | WILSON TROY EDWARD | Director | A-Award | A | COMMON STOCK | 27,858 | 0.00 | — | 28,208 | — | ↗ |
| 2021-06-15 | Stuglik Brian M | Director | A-Award | A | COMMON STOCK | 27,858 | 0.00 | — | 27,858 | — | ↗ |
| 2021-06-15 | Senderowicz Adrian | Director | A-Award | A | COMMON STOCK | 27,858 | 0.00 | — | 27,858 | — | ↗ |
| 2021-06-15 | Miller Ann Calby | Director | A-Award | A | COMMON STOCK | 27,858 | 0.00 | — | 40,732 | — | ↗ |
| 2021-06-15 | MOYES JAY M | Director | A-Award | A | Common Stock | 27,858 | 0.00 | — | 34,180 | — | ↗ |
| 2021-06-15 | MILLER MICHAEL PATRICK | Director | A-Award | A | COMMON STOCK | 27,858 | 0.00 | — | 78,511 | — | ↗ |
| 2021-06-11 | Senderowicz Adrian | Director | S-Sale | D | COMMON STOCK | 40,993 | 11.17 | 457.8K | 0 | — | ↗ |
| 2021-06-10 | WILSON TROY EDWARD | Director | S-Sale | D | COMMON STOCK | 25,748 | 11.36 | 292.4K | 350 | — | ↗ |
| 2021-06-10 | Miller Ann Calby | Director | S-Sale | D | COMMON STOCK | 12,874 | 11.43 | 147.2K | 12,874 | — | ↗ |
| 2021-06-10 | MOYES JAY M | Director | S-Sale | D | Common Stock | 25,248 | 11.36 | 286.9K | 6,322 | — | ↗ |
| 2021-06-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 152 | 10.74 | 1.6K | 68,218 | — | ↗ |
| 2021-06-02 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 416 | 10.77 | 4.5K | 67,959 | — | ↗ |
| 2021-06-02 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 1,757 | 10.74 | 18.9K | 4,426,650 | — | ↗ |
| 2021-05-03 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 152 | 9.91 | 1.5K | 68,370 | — | ↗ |
| 2021-05-03 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 417 | 9.91 | 4.1K | 68,375 | — | ↗ |
| 2021-05-03 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 1,758 | 9.01 | 15.8K | 4,428,407 | — | ↗ |
| 2021-04-05 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 155 | 9.80 | 1.5K | 68,522 | — | ↗ |
| 2021-04-05 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 426 | 9.80 | 4.2K | 68,792 | — | ↗ |
| 2021-04-05 | BRYCE RICHARD PAUL | Officer | S-Sale | D | COMMON STOCK | 426 | 9.80 | 4.2K | 121,662 | — | ↗ |
| 2021-04-05 | AUERBACH ALAN H | Director / Officer / 10% Owner | S-Sale | D | COMMON STOCK | 1,584 | 9.80 | 15.5K | 4,430,165 | — | ↗ |
| 2021-03-02 | NOUGUES MAXIMO F | Officer | S-Sale | D | COMMON STOCK | 154 | 10.14 | 1.6K | 68,677 | — | ↗ |
| 2021-03-02 | HUNT DOUGLAS M | Officer | S-Sale | D | COMMON STOCK | 422 | 10.16 | 4.3K | 69,218 | — | ↗ |
| 2021-03-02 | BRYCE RICHARD PAUL | Officer | S-Sale | D | COMMON STOCK | 422 | 10.15 | 4.3K | 122,088 | — | ↗ |
Executive team
Top executives
EBIT / Employee
246.5K
Shares Outstanding
50.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Alan H. Auerbach President and Chief Executive Officer | 931.3K | — | 551.5K | 535.5K | 1.03M | 16.6K | 3.06M | 35.50% | ↗ |
| 2 | 2025 | Jeff J. Ludwig Chief Commercial Officer | 264.9K | — | 133.0K | 129.1K | — | 949.2K | 1.48M | 17.76% | ↗ |
| 3 | 2025 | Maximo F. Nougues Chief Financial Officer | 563.0K | 130.6K | 170.8K | 165.9K | 191.1K | 19.8K | 1.24M | 27.13% | ↗ |
| 4 | 2025 | Douglas Hunt, B.Sc. (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 489.1K | 122.3K | 133.8K | 129.9K | 166.0K | 20.4K | 1.06M | 24.84% | ↗ |
| 5 | 2024 | Alan H. Auerbach President and Chief Executive Officer | 904.2K | — | 1.06M | 1.06M | 938.6K | 16.2K | 3.97M | 53.17% | ↗ |
| 6 | 2024 | Alan H. Auerbach President and Chief Executive Officer | 904.2K | — | 1.06M | 1.06M | 938.6K | 16.2K | 3.97M | 53.17% | ↗ |
| 7 | 2024 | Maximo F. Nougues Chief Financial Officer | 538.7K | 123.9K | 275.4K | 275.4K | 172.1K | 19.5K | 1.40M | 39.21% | ↗ |
| 8 | 2024 | Maximo F. Nougues Chief Financial Officer | 538.7K | 123.9K | 275.4K | 275.4K | 172.1K | 19.5K | 1.40M | 39.21% | ↗ |
| 9 | 2024 | Alvin Wong, Pharm.D. Chief Scientific Officer | 413.7K | — | 275.4K | 275.4K | — | 374.3K | 1.34M | 41.14% | ↗ |
| 10 | 2024 | Jeff J. Ludwig Chief Commercial Officer | 608.5K | 60.9K | 172.1K | 172.1K | 194.4K | 20.3K | 1.23M | 28.03% | ↗ |
| 11 | 2024 | Jeff J. Ludwig Chief Commercial Officer | 608.5K | 60.9K | 172.1K | 172.1K | 194.4K | 20.3K | 1.23M | 28.03% | ↗ |
| 12 | 2024 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 461.9K | 106.2K | 241.0K | 241.0K | 147.5K | 19.9K | 1.22M | 39.59% | ↗ |
| 13 | 2024 | Douglas Hunt, B.Sc. (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 461.9K | 106.2K | 241.0K | 241.0K | 147.5K | 19.9K | 1.22M | 39.59% | ↗ |
| 14 | 2023 | Alan H. Auerbach President and Chief Executive Officer | 877.9K | — | 818.3K | 821.8K | 408.0K | 18.7K | 2.94M | 55.70% | ↗ |
| 15 | 2023 | Alan H. Auerbach President and Chief Executive Officer | 877.9K | — | 818.3K | 821.8K | 408.0K | 18.7K | 2.94M | 55.70% | ↗ |
| 16 | 2023 | Jeff J. Ludwig Chief Commercial Officer | 596.6K | 77.6K | 294.0K | 295.3K | 85.3K | 33.1K | 1.38M | 42.64% | ↗ |
| 17 | 2023 | Jeff J. Ludwig Chief Commercial Officer | 596.6K | 77.6K | 294.0K | 295.3K | 85.3K | 33.1K | 1.38M | 42.64% | ↗ |
| 18 | 2023 | Alvin Wong, Pharm.D. Chief Scientific Officer | 524.2K | 99.6K | 275.4K | 275.4K | 75.0K | 15.5K | 1.27M | 43.54% | ↗ |
| 19 | 2023 | Maximo F. Nougues Chief Financial Officer | 515.5K | 108.3K | 257.3K | 258.4K | 73.7K | 18.7K | 1.23M | 41.86% | ↗ |
| 20 | 2023 | Maximo F. Nougues Chief Financial Officer | 515.5K | 108.3K | 257.3K | 258.4K | 73.7K | 18.7K | 1.23M | 41.86% | ↗ |
| 21 | 2023 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer | 428.0K | 89.9K | 211.3K | 212.2K | 61.2K | 18.9K | 1.02M | 41.46% | ↗ |
| 22 | 2023 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 428.0K | 89.9K | 211.3K | 212.2K | 61.2K | 18.9K | 1.02M | 41.46% | ↗ |
| 23 | 2023 | Douglas Hunt, B.Sc. (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 428.0K | 89.9K | 211.3K | 212.2K | 61.2K | 18.9K | 1.02M | 41.46% | ↗ |
| 24 | 2022 | Alan H. Auerbach President and Chief Executive Officer | 852.3K | — | 393.4K | 394.8K | 877.5K | 14.7K | 2.53M | 31.12% | ↗ |
| 25 | 2022 | Jeff J. Ludwig Chief Commercial Officer | 573.6K | 131.9K | 91.1K | 91.5K | 181.7K | 29.6K | 1.10M | 16.61% | ↗ |
| 26 | 2022 | Maximo F. Nougues Chief Financial Officer | 495.7K | 114.0K | 144.9K | 145.4K | 157.0K | 14.7K | 1.07M | 27.09% | ↗ |
| 27 | 2022 | Alvin Wong, Pharm.D. Chief Scientific Officer | 504.0K | 115.9K | 104.6K | 105.0K | 159.7K | 30.1K | 1.02M | 20.56% | ↗ |
| 28 | 2022 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer | 398.2K | 91.6K | 52.8K | 53.0K | 126.1K | 16.8K | 738.4K | 14.32% | ↗ |
| 29 | 2022 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer | 398.2K | 91.6K | 52.8K | 53.0K | 126.1K | 16.8K | 738.4K | 14.32% | ↗ |
| 30 | 2022 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 398.2K | 91.6K | 52.8K | 53.0K | 126.1K | 16.8K | 738.4K | 14.32% | ↗ |
| 31 | 2021 | Alan H. Auerbach President and Chief Executive Officer | 827.5K | — | 1.80M | 15.54M | 268.9K | 14.1K | 18.45M | 93.98% | ↗ |
| 32 | 2021 | Maximo F. Nougues Chief Financial Officer | 472.1K | 94.4K | 668.3K | 668.2K | 47.2K | 14.1K | 1.96M | 68.04% | ↗ |
| 33 | 2021 | Jeff J. Ludwig Chief Commercial Officer | 562.4K | 90.0K | 433.5K | 433.5K | 56.2K | 26.4K | 1.60M | 54.12% | ↗ |
| 34 | 2021 | Alvin Wong, Pharm.D. Chief Scientific Officer | 459.4K | 96.0K | 84.7K | 652.0K | 48.0K | 22.4K | 1.36M | 54.07% | ↗ |
| 35 | 2021 | Alvin Wong, Pharm.D. Chief Scientific Officer | 459.4K | 96.0K | 84.7K | 652.0K | 48.0K | 22.4K | 1.36M | 54.07% | ↗ |
| 36 | 2021 | Douglas Hunt, B.Sc (Hons) Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer | 379.2K | 75.8K | 237.5K | 237.4K | 37.9K | 16.1K | 984.0K | 48.27% | ↗ |
| 37 | 2021 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 379.2K | 75.8K | 237.5K | 237.4K | 37.9K | 16.1K | 984.0K | 48.27% | ↗ |
| 38 | 2020 | Alan H. Auerbach President and Chief Executive Officer | 834.3K | — | 1.57M | 1.57M | 417.8K | 13.8K | 4.41M | 71.32% | ↗ |
| 39 | 2020 | Jeff J. Ludwig Chief Commercial Officer | 435.4K | 807.5K | — | 1.98M | 66.0K | 4.5K | 3.29M | 60.10% | ↗ |
| 40 | 2020 | Jeff J. Ludwig Chief Commercial Officer | 435.4K | 807.5K | — | 1.98M | 66.0K | 4.5K | 3.29M | 60.10% | ↗ |
| 41 | 2020 | Richard P. Bryce, MBChB, MRCGP and MFPM Former Chief Medical and Scientific Officer | 501.6K | 85.3K | 630.0K | 534.0K | 80.2K | 18.0K | 1.85M | 62.95% | ↗ |
| 42 | 2020 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 364.6K | 87.5K | 534.0K | 534.0K | 58.3K | 15.5K | 1.59M | 67.00% | ↗ |
| 43 | 2020 | Maximo F. Nougues Chief Financial Officer | 460.6K | 87.5K | 192.0K | 151.6K | 73.7K | 13.8K | 979.1K | 35.09% | ↗ |
| 44 | 2019 | Alan H. Auerbach President and Chief Executive Officer | 780.0K | 507.0K | 1.09M | 1.37M | — | 13.1K | 3.76M | 65.38% | ↗ |
| 45 | 2019 | Alan H. Auerbach President and Chief Executive Officer | 780.0K | 507.0K | 1.09M | — | — | 13.1K | 3.76M | 28.99% | ↗ |
| 46 | 2019 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 350.6K | 161.7K | 518.5K | 336.0K | — | 12.0K | 1.38M | 61.98% | ↗ |
| 47 | 2019 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 482.3K | 221.8K | 274.8K | 336.0K | — | 16.2K | 1.33M | 45.89% | ↗ |
| 48 | 2019 | Richard P. Bryce, MBChB, MRCGP and MFPM Former Chief Medical and Scientific Officer | 482.3K | 221.8K | 274.8K | 336.0K | — | 16.2K | 1.33M | 45.89% | ↗ |
| 49 | 2019 | Steven Lo Chief Commercial Officer | 468.5K | — | — | 792.0K | — | 57.4K | 1.32M | 60.09% | ↗ |
| 50 | 2019 | Maximo F. Nougues Chief Financial Officer | 445.0K | 207.7K | — | — | — | 13.1K | 665.8K | 0.00% | ↗ |
| 51 | 2019 | Maximo F. Nougues Chief Financial Officer | 445.0K | 207.7K | — | — | — | 13.1K | 665.8K | 0.00% | ↗ |
| 52 | 2018 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 329.7K | 149.1K | — | 6.27M | — | 2.8K | 6.75M | 92.87% | ↗ |
| 53 | 2018 | Douglas Hunt, B.Sc (Hons). Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | 329.7K | 149.1K | — | 6.27M | — | 2.8K | 6.75M | 92.87% | ↗ |
| 54 | 2018 | Alan H. Auerbach President and Chief Executive Officer | 757.3K | 541.4K | 2.17M | 2.67M | — | 12.3K | 6.15M | 78.69% | ↗ |
| 55 | 2018 | Alan H. Auerbach President and Chief Executive Officer | 757.3K | 541.4K | 2.17M | — | — | 12.3K | 6.15M | 35.26% | ↗ |
| 56 | 2018 | Maximo F. Nougues Chief Financial Officer | 71.0K | 550.0K | — | — | — | 158.00 | 2.28M | 0.00% | ↗ |
| 57 | 2018 | Maximo F. Nougues Chief Financial Officer | 71.0K | 550.0K | — | 1.66M | — | 158.00 | 2.28M | 72.77% | ↗ |
| 58 | 2018 | Steven Lo Chief Commercial Officer | 468.9K | 206.3K | — | 1.55M | — | 12.3K | 2.24M | 69.26% | ↗ |
| 59 | 2018 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 468.2K | 206.0K | 547.7K | 657.0K | — | 14.9K | 1.89M | 63.61% | ↗ |
| 60 | 2018 | Richard P. Bryce, MBChB, MRCGP and MFPM Former Chief Medical and Scientific Officer | 468.2K | 206.0K | 547.7K | — | — | 14.9K | 1.89M | 28.92% | ↗ |
| 61 | 2018 | Charles R. Eyler Senior Vice President, Finance and Administration | 425.2K | 187.1K | 547.7K | 657.0K | — | 19.2K | 1.84M | 65.61% | ↗ |
| 62 | 2017 | Charles R. Eyler Senior Vice President, Finance and Administration | 406.9K | 156.6K | 1.61M | 738.2K | — | 19.7K | 2.93M | 80.08% | ↗ |
| 63 | 2017 | Alan H. Auerbach President and Chief Executive Officer | 732.5K | 404.4K | — | 1.64M | — | 10.6K | 2.79M | 58.84% | ↗ |
| 64 | 2017 | Steven Lo Chief Commercial Officer | 455.3K | 200.3K | — | 738.2K | — | 12.5K | 1.41M | 52.49% | ↗ |
| 65 | 2017 | Richard P. Bryce Chief Medical and Scientific Officer | 430.5K | 175.0K | — | 738.2K | — | 12.6K | 1.36M | 54.43% | ↗ |
| 66 | 2017 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 430.5K | 175.0K | — | 738.2K | — | 12.6K | 1.36M | 54.43% | ↗ |
| 67 | 2016 | Alan H. Auerbach President and Chief Executive Officer | 706.0K | 542.7K | 8.15M | 1.44M | — | 13.8K | 10.86M | 88.37% | ↗ |
| 68 | 2016 | Robert Charnas Senior Vice President, Regulatory Affairs and Project Management | 165.4K | 145.6K | 1.71M | 1.63M | — | 5.7K | 3.66M | 91.36% | ↗ |
| 69 | 2016 | Richard P. Bryce Chief Medical and Scientific Officer | 395.4K | 225.3K | 1.71M | 892.6K | — | 13.8K | 3.24M | 80.41% | ↗ |
| 70 | 2016 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 395.4K | 225.3K | 1.71M | 892.6K | — | 13.8K | 3.24M | 80.41% | ↗ |
| 71 | 2016 | Richard P. Bryce Senior Vice President, Clinical Research and Development | 395.4K | 225.3K | 1.71M | 892.6K | — | 13.8K | 3.24M | 80.41% | ↗ |
| 72 | 2016 | Steven Lo Chief Commercial Officer | 435.6K | 270.1K | 1.71M | 649.2K | — | 14.2K | 3.08M | 76.63% | ↗ |
| 73 | 2016 | Charles R. Eyler Senior Vice President, Finance and Administration | 384.2K | 207.3K | 570.7K | 649.2K | — | 14.0K | 1.83M | 66.83% | ↗ |
| 74 | 2015 | Steven Lo Chief Commercial Officer | 133.8K | 1.11M | — | — | — | 247.00 | 9.20M | 0.00% | ↗ |
| 75 | 2015 | Alan H. Auerbach President and Chief Executive Officer | 651.0K | 343.4K | — | 6.84M | — | 11.3K | 7.84M | 87.18% | ↗ |
| 76 | 2015 | Alan H. Auerbach President and Chief Executive Officer | 651.0K | 315.0K | — | 6.84M | — | 11.3K | 7.82M | 87.50% | ↗ |
| 77 | 2015 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 371.8K | 161.1K | — | 1.59M | — | 12.7K | 2.14M | 74.49% | ↗ |
| 78 | 2015 | Richard P. Bryce Chief Medical and Scientific Officer | 371.8K | 138.4K | — | 1.59M | — | 12.7K | 2.12M | 75.29% | ↗ |
| 79 | 2015 | Richard P. Bryce Senior Vice President, Clinical Research and Development | 371.8K | 138.4K | — | 1.59M | — | 12.7K | 2.12M | 75.29% | ↗ |
| 80 | 2015 | Charles R. Eyler Senior Vice President, Finance and Administration | 344.5K | 139.6K | — | 1.42M | — | 17.5K | 1.92M | 73.87% | ↗ |
| 81 | 2015 | Charles R. Eyler Senior Vice President, Finance and Administration | 344.5K | 134.1K | — | 1.42M | — | 17.5K | 1.91M | 74.08% | ↗ |
| 82 | 2014 | Alan H. Auerbach President and Chief Executive Officer | 610.0K | 305.0K | — | 16.88M | — | 11.0K | 17.80M | 94.80% | ↗ |
| 83 | 2014 | Alan H. Auerbach President and Chief Executive Officer | 610.0K | 300.0K | — | 16.88M | — | 11.0K | 17.80M | 94.82% | ↗ |
| 84 | 2014 | Charles R. Eyler Senior Vice President, Finance and Administration | 304.3K | 123.1K | — | 4.06M | — | 15.7K | 4.51M | 90.16% | ↗ |
| 85 | 2014 | Charles R. Eyler Senior Vice President, Finance and Administration | 304.3K | 117.6K | — | 4.06M | — | 15.7K | 4.50M | 90.27% | ↗ |
| 86 | 2014 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 342.7K | 133.1K | — | 1.45M | — | 12.2K | 1.94M | 74.80% | ↗ |
| 87 | 2014 | Richard P. Bryce Senior Vice President, Clinical Research and Development | 342.7K | 130.7K | — | 1.45M | — | 12.2K | 1.93M | 74.89% | ↗ |
| 88 | 2014 | Richard B. Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance | 313.5K | 115.8K | — | — | — | 3.8K | 433.1K | 0.00% | ↗ |
| 89 | 2013 | Alan H. Auerbach President and Chief Executive Officer | 546.7K | 260.0K | — | 4.56M | — | 10.6K | 5.37M | 84.79% | ↗ |
| 90 | 2013 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 322.7K | 110.3K | — | 1.40M | — | 18.6K | 1.85M | 75.59% | ↗ |
| 91 | 2013 | Charles R. Eyler Senior Vice President, Finance and Administration | 282.9K | 83.5K | — | 901.2K | — | 15.8K | 1.28M | 70.22% | ↗ |
| 92 | 2013 | Richard B. Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance | 289.2K | 86.0K | — | 901.2K | — | 2.5K | 1.28M | 70.47% | ↗ |
| 93 | 2012 | Alan H. Auerbach President and Chief Executive Officer | 470.0K | 235.0K | — | 2.60M | — | 25.82M | 29.12M | 8.93% | ↗ |
| 94 | 2012 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | 167.2K | 50.0K | — | 829.5K | — | 18.8K | 1.07M | 77.85% | ↗ |
| 95 | 2012 | Richard B. Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance | 271.1K | 80.4K | — | 674.7K | — | 3.0K | 1.03M | 65.55% | ↗ |
| 96 | 2012 | Charles R. Eyler Senior Vice President, Finance and Administration | 269.4K | 79.5K | — | 549.7K | — | 16.9K | 915.5K | 60.04% | ↗ |
| 97 | 2011 | Alan H. Auerbach President and Chief Executive Officer | 156.7K | — | — | — | — | — | 156.7K | 0.00% | ↗ |
| 98 | 2011 | Alan H. Auerbach President and Chief Executive Officer | 156.7K | — | — | — | — | — | 156.7K | 0.00% | ↗ |
| 99 | 2011 | Charles R. Eyler Senior Vice President, Finance and Administration | 110.4K | — | — | — | — | — | 110.4K | 0.00% | ↗ |
| 100 | 2011 | Charles R. Eyler Senior Vice President, Finance and Administration | 110.4K | — | — | — | — | — | 110.4K | 0.00% | ↗ |
| 101 | 2011 | Richard B. Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance | 67.0K | — | — | — | — | — | 67.0K | 0.00% | ↗ |
| 102 | 2011 | Richard Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance | 67.0K | — | — | — | — | — | 67.0K | 0.00% | ↗ |
| 103 | 2011 | Richard P. Bryce, MBChB, MRCGP and MFPM Senior Vice President, Clinical Research and Development | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary | 2M | male |
| Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer | 904.5K | male |
| Douglas Hunt FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | 797.8K | male |
| Heather Blaber | Senior Vice President of Marketing | — | female |
| Mariann Ohanesian | Senior Director of Investor Relations | — | male |
| Roger L. Storms | Senior Vice President of Sales | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PBYI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
